We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+0.15%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$474M
AUM Growth
+$427M
Cap. Flow
+$433M
Cap. Flow %
91.18%
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$6.86M
2
BBDC icon
Barings BDC
BBDC
+$6.33M
3
OXSQ icon
Oxford Square Capital
OXSQ
+$5.45M
4
ECC
Eagle Point Credit Company
ECC
+$5.29M
5
FSK icon
FS KKR Capital
FSK
+$5.24M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$2.25M
2
ACOR
Acorda Therapeutics
ACOR
+$644K
3
ARRY
Array Biopharma Inc
ARRY
+$605K
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$603K
5
QURE icon
uniQure
QURE
+$374K

Sector Composition

Rank Sector Weight
1 Financials 23.58%
2 Real Estate 14.99%
3 Energy 13.55%
4 Healthcare 12.23%
5 Materials 8.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKBA icon
201
Akebia Therapeutics
AKBA
$327M
$315K 0.07%
65,063
+31,549
+94% +$179K
CYTK icon
202
Cytokinetics
CYTK
$11B
$315K 0.07%
27,962
-5,796
-17% -$55.9K
RETA
203
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$309K 0.07%
3,273
-1,123
-26% -$97K
SGMO
204
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$308K 0.06%
+28,643
New +$305K
TCDA
205
DELISTED
Tricida, Inc. Common Stock
TCDA
$306K 0.06%
7,762
-865
-10% -$30.4K
FATE icon
206
Fate Therapeutics
FATE
$281M
$304K 0.06%
14,965
-1,647
-10% -$29.7K
CBAY
207
DELISTED
Cymabay Therapeutics
CBAY
$304K 0.06%
42,473
+11,526
+37% +$131K
GRTS
208
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$302K 0.06%
+27,130
New +$310K
AGEN
209
Agenus
AGEN
$249M
$301K 0.06%
5,109
-367
-7% -$20K
AXSM icon
210
Axsome Therapeutics
AXSM
$12.4B
$301K 0.06%
+11,692
New +$234K
PHAS
211
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$301K 0.06%
+22,949
New +$281K
PRTA icon
212
Prothena Corp
PRTA
$458M
$300K 0.06%
28,379
+5,461
+24% +$56.1K
PTCT icon
213
PTC Therapeutics
PTCT
$6.37B
$300K 0.06%
6,660
-1,287
-16% -$50.8K
VYGR icon
214
Voyager Therapeutics
VYGR
$187M
$300K 0.06%
11,011
-14,640
-57% -$335K
IMMU
215
DELISTED
Immunomedics Inc
IMMU
$299K 0.06%
+21,587
New +$325K
BCRX icon
216
BioCryst Pharmaceuticals
BCRX
$2.37B
$298K 0.06%
78,684
+47,407
+152% +$285K
TCRT icon
217
Alaunos Therapeutics
TCRT
$4.74M
$298K 0.06%
341
-273
-44% -$188K
KYNB
218
Kyntra Bio
KYNB
$28.5M
$297K 0.06%
263
-11
-4% -$12K
KALV
219
DELISTED
KalVista Pharmaceuticals
KALV
$297K 0.06%
+13,395
New +$314K
MGNX icon
220
MacroGenics
MGNX
$235M
$297K 0.06%
+17,519
New +$301K
ATNX
221
DELISTED
Athenex, Inc. Common Stock
ATNX
$297K 0.06%
749
-324
-30% -$89.8K
CCXI
222
DELISTED
ChemoCentryx, Inc.
CCXI
$297K 0.06%
31,973
+5,521
+21% +$63.9K
DNLI icon
223
Denali Therapeutics
DNLI
$3.67B
$296K 0.06%
14,246
+1,045
+8% +$23.4K
TVRD
224
Tvardi Therapeutics
TVRD
$23.5M
$296K 0.06%
+383
New +$269K
ADVM
225
DELISTED
Adverum Biotechnologies
ADVM
$293K 0.06%
+2,465
New +$204K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q2 2019 Portfolio in Review

As of Q2 2019, Virtus ETF Advisers held 454 positions worth $474M, up 909% from $47M the previous quarter. Its ten largest holdings account for 11% of the portfolio.

Virtus ETF Advisers deployed $433M of net new capital in Q2 2019, opening 296 new positions and adding to 64 existing holdings. Its largest new stake was Oxford Lane Capital: 132,284 shares worth $6.67M.

By sector, the portfolio is most concentrated in Financials at 24% of assets, up from 0.73% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $605K trimmed.

  • Virtus ETF Advisers's largest Q2 2019 buy was Oxford Lane Capital: 132,284 shares worth $6.67M.
  • Virtus ETF Advisers added most to Dominion Energy in Q2 2019, an estimated $2.63M increase.
  • Virtus ETF Advisers's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $605K.
  • Virtus ETF Advisers fully exited Spark Therapeutics, Inc. Common Stock in Q2 2019, selling an estimated $2.25M.
  • Virtus ETF Advisers's ten largest holdings make up 11% of its $474M portfolio in Q2 2019.
  • Virtus ETF Advisers opened 296 new positions and closed 20 in Q2 2019.
  • Virtus ETF Advisers's portfolio value rose 909% quarter-over-quarter to $474M.

Based on Virtus ETF Advisers's 13F filing for Q2 2019, filed 13 Aug 2019.